Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Aug;69(2):341-50.
doi: 10.1086/321967. Epub 2001 Jul 6.

Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23

Affiliations

Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23

J Xu et al. Am J Hum Genet. 2001 Aug.

Abstract

Multiple lines of evidence have implicated the short arm of chromosome 8 as harboring genes important in prostate carcinogenesis. Although most of this evidence comes from the identification of frequent somatic alterations of 8p loci in prostate cancer cells (e.g., loss of heterozygosity), studies have also suggested a role for 8p genes in mediation of inherited susceptibility to prostate cancer. To further examine this latter possibility, we performed linkage analyses, in 159 pedigrees affected by hereditary prostate cancer (HPC), using 24 markers on the short arm of chromosome 8. In the complete set of families, evidence for prostate cancer linkage was found at 8p22-23, with a peak HLOD of 1.84 (P=.004), and an estimate of the proportion of families linked (alpha) of 0.14, at D8S1130. In the 79 families with average age at diagnosis >65 years, an allele-sharing LOD score of 2.64 (P=.0005) was observed, and six markers spanning a distance of 10 cM had LOD scores >2.0. Interestingly, the small number of Ashkenazi Jewish pedigrees (n=11) analyzed in this study contributed disproportionately to this linkage. Mutation screening in HPC probands and association analyses in case subjects (a group that includes HPC probands and unrelated case subjects) and unaffected control subjects were carried out for the putative prostate cancer-susceptibility gene, PG1, previously localized to the 8p22-23 region. No statistical differences in the allele, genotype, or haplotype frequencies of the SNPs or other sequence variants in the PG1 gene were observed between case and control subjects. However, case subjects demonstrated a trend toward higher homozygous rates of less-frequent alleles in all three PG1 SNPs, and overtransmission of a PG1 variant to case subjects was observed. In summary, these results provide evidence for the existence of a prostate cancer-susceptibility gene at 8p22-23. Evaluation of the PG1 gene and other candidate genes in this area appears warranted.

PubMed Disclaimer

Figures

Figure  1
Figure 1
Results of multipoint parametric and nonparametric linkage analyses of prostate cancer–susceptibility loci, using 24 markers (21 microsatellite markers and 3 SNPs) on chromosome 8p22-23 in 159 families affected by HPC. The solid line represents parametric LOD under the assumption of heterogeneity. The dotted line represents allele-sharing LOD. Each diamond and circle represents a marker.

Similar articles

Cited by

References

Electronic-Database Information

    1. GDA: Software for the Analysis of Discrete Genetic Data, http://lewis.eeb.uconn.edu/lewishome/gda.html
    1. Haplotype Information Help Page, http://www.bioinf.mdc-berlin.de/hap/ithap-help.html
    1. Linkage Designer, http://dnalab-www.uia.ac.be/dnalab/ld.html
    1. Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for prostate cancer [MIM 176807], HPC2 [MIM 605367], HPC1 [MIM 601518], PCaP [MIM 602759], PCBP/CAPB [MIM 603688], and HPCX [MIM 300147])
    1. Weeks FTP page, ftp://watson.hgen.pitt.edu (for FASTSLINK)

References

    1. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB (1996) Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics 35:46–54 - PubMed
    1. Bookstein R (2001) Tumor suppressor genes in prostate cancer. In: Chung LWK, Isaacs WB, Simons JW (eds) Prostate cancer, biology, genetics, and the new therapeutics. Humana Press, Totowa, NJ
    1. Broman KW, Murray JC, Sheffield VC, White RL, Weber JL (1998) Comprehensive human genetic maps: individual and sex-specific variation in recombination. Am J Hum Genet 63:861–689 - PMC - PubMed
    1. Chuaqui RF, Sanz-Ortega J, Vocke C, Linehan WM, Sanz-Esponera J, Zhuang Z, Emmert-Buck MR, Merino MJ (1995) Loss of heterozygosity on the short arm of chromosome 8 in male breast carcinomas. Cancer Res 55:4995–4998 - PubMed
    1. Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC, Jenkins RB (1993) Human epithelial ovarian cancer allelotype. Cancer Res 53:2393–2398 - PubMed

Publication types

MeSH terms

Substances